Grip Molecular Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Series A
- (Upcoming)
- Latest Deal Amount
-
$15M
- Investors
-
7
Grip Molecular General Information
Description
Developer of a CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)-based diagnostic platform designed to provide molecular-level accuracy in infectious disease testing at the point of care or point of need. The company offers proprietary gene-editing chemistry integrated into a lateral flow format, enabling healthcare providers and decentralized testing environments to obtain laboratory-grade sensitivity and specificity in a simple, low-cost format.
Contact Information
Website
www.gripmolecular.comCorporate Office
- 1000 Westgate Drive
- Suite 122
- Saint Paul, MN 55114
- United States
Corporate Office
- 1000 Westgate Drive
- Suite 122
- Saint Paul, MN 55114
- United States
Grip Molecular Timeline
Grip Molecular Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 14. Later Stage VC (Series A) | 01-Jan-2027 | $15M | Upcoming | Pre-Clinical Trials | ||
| 13. Later Stage VC | 29-Oct-2026 | Completed | Pre-Clinical Trials | |||
| 12. Seed Round | 20-Feb-2026 | Completed | Pre-Clinical Trials | |||
| 11. Grant | 07-Mar-2023 | Completed | Product In Beta Test | |||
| 10. Grant | 28-Oct-2022 | Completed | Product In Beta Test | |||
| 9. Grant | 26-Oct-2022 | Completed | Product In Beta Test | |||
| 8. Seed Round | 11-Dec-2020 | Completed | Product In Beta Test | |||
| 7. Accelerator/Incubator | Completed | Product In Beta Test | ||||
| 6. Accelerator/Incubator | 29-Sep-2020 | $50K | $50K | Completed | Product In Beta Test | |
| 5. Grant | 24-Aug-2020 | $27K | Completed | Product In Beta Test |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Grip Molecular Patents
Grip Molecular Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026169752-A1 | Crispr cascade methods for detecting target nucleic acids and kits and devices for practicing the same | Pending | 07-Feb-2025 | ||
| WO-2026151762-A1 | Methods and kits for detecting target nucleic acids using crispr associated proteases | Pending | 09-Jan-2025 | ||
| US-11666907-B2 | Methods, devices, and systems for detecting analytes | Active | 29-Sep-2017 | ||
| US-12208390-B2 | Methods, devices, and systems for detecting analytes | Active | 29-Sep-2017 | ||
| US-20190262827-A1 | Methods, devices, and systems for detecting analytes | Active | 29-Sep-2017 | C12Q1/6825 |
Grip Molecular Signals
Grip Molecular Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| gBETA | Accelerator/Incubator | Minority | ||
| EvoNexus | Accelerator/Incubator | Minority | ||
| Minnesota Department of Employment and Economic Development | Government | |||
| University of Minnesota Office for Technology Commercialization | University | |||
| University of Minnesota | University |
Grip Molecular FAQs
-
When was Grip Molecular founded?
Grip Molecular was founded in 2019.
-
Where is Grip Molecular headquartered?
Grip Molecular is headquartered in Saint Paul, MN.
-
What is the size of Grip Molecular?
Grip Molecular has 7 total employees.
-
What industry is Grip Molecular in?
Grip Molecular’s primary industry is Diagnostic Equipment.
-
Is Grip Molecular a private or public company?
Grip Molecular is a Private company.
-
What is Grip Molecular’s current revenue?
The current revenue for Grip Molecular is .
-
How much funding has Grip Molecular raised over time?
Grip Molecular has raised $15.4M.
-
Who are Grip Molecular’s investors?
gBETA, EvoNexus, Minnesota Department of Employment and Economic Development, University of Minnesota Office for Technology Commercialization, and University of Minnesota are 5 of 7 investors who have invested in Grip Molecular.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process